RFK Jr. pulls $500mn in funding for development of thimerosal-free flu vaccines
Robert F. Kennedy Jr. announced in a statement Tuesday that 22 projects, totaling $500 million, to develop vaccines using mRNA technology will be halted.
Kennedy's decision to terminate the projects is the latest in a string of decisions that have put the longtime vaccine critic's doubts about shots into full effect at the nation's health department. Kennedy has pulled back recommendations around the COVID-19 shots, fired the panel that makes vaccine recommendations, and refused to offer a vigorous endorsement of vaccinations as a measles outbreak worsened.
The health secretary criticized mRNA vaccines in a video on his social media accounts, explaining the decision to cancel projects being led by the nation's leading pharmaceutical companies, including Pfizer and Moderna, that offer protection against viruses like the flu, COVID-19 and H5N1.
'To replace the troubled mRNA programs, we're prioritizing the development of safer, broader vaccine strategies, like whole-virus vaccines and novel platforms that don't collapse when viruses mutate," Kennedy said in the video.
Infectious disease experts say the mRNA technology used in vaccines is safe, and they credit its development during the first Trump administration with slowing the 2020 coronavirus pandemic. Future pandemics, they warned, will be harder to stop without the help of mRNA.
'I don't think I've seen a more dangerous decision in public health in my 50 years in the business,' said Mike Osterholm, a University of Minnesota expert on infectious diseases and pandemic preparations.
He noted mRNA technology offers potential advantages of rapid production, crucial in the event of a new pandemic that requires a new vaccine.
The shelving of the mRNA projects is short-sighted as concerns about a bird flu pandemic continue to loom, said Dr. Paul Offit, a vaccine expert at Children's Hospital of Philadelphia.
'It's certainly saved millions of lives,' Offit said of the existing mRNA vaccines.
Scientists are using mRNA for more than infectious disease vaccines, with researchers around the world exploring its use for cancer immunotherapies. At the White House earlier this year, billionaire tech entrepreneur Larry Ellison praised mRNA for its potential to treat cancer.
Traditionally, vaccines have required growing pieces of viruses, often in chicken eggs or giant vats of cells, then purifying that material. The mRNA approach starts with a snippet of genetic code that carries instructions for making proteins. Scientists pick the protein to target, inject that blueprint and the body makes just enough to trigger immune protection — producing its own vaccine dose.
In a statement Tuesday, HHS said 'other uses of mRNA technology within the department are not impacted by this announcement."
The mRNA technology is used in approved COVID-19 and RSV shots, but has not yet been approved for a flu shot. Moderna, which was studying a combination COVID-19 and flu mRNA shot, had said it believed mRNA could speed up production of flu shots compared with traditional vaccines.
The abandoned mRNA projects signal a 'shift in vaccine development priorities,' the health department said in its statement, adding that it will start 'investing in better solutions.'
'Let me be absolutely clear, HHS supports safe, effective vaccines for every American who wants them," Kennedy said in the statement.
Speaking hours later Tuesday at a news conference in Anchorage, Alaska, alongside the state's two Republican U.S. senators, Kennedy said work is underway on an alternative.
He said a 'universal vaccine' that mimics 'natural immunity" is the administration's focus.
'It could be effective — we believe it's going to be effective -- against not only coronaviruses, but also flu,' he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
28 minutes ago
- Time of India
People with Covid-19 history show increased severity of Malaria and Dengue: Study
Mangaluru: A new research study conducted by a medical college in the city found that individuals who were infected with Covid-19 infection experienced a higher incidence of severe malaria and dengue compared to those without a history of it. A case-control study was conducted at the department of community medicine at Kasturba Medical College, Mangaluru. It was published in the 'BMC Infectious Diseases' journal recently. The study was conducted by Dr Prasanna Mithra, Dr Rekha T, Dr Nithin Kumar, Dr Ramesh Holla, Dr Mithun Rao, and Dr Bhaskaran Unnikrishnan from the department of community medicine, KMC, Mangaluru. Dr Naveen Chandra Kulal, who was the district vector-borne disease control programme officer, was also part of the study. Dr Mithra told TOI that the research indicated that previous Covid-19 infection exacerbated the seriousness of these diseases, particularly among individuals with additional risk factors such as socioeconomic status, education level, and occupation. The case-control study involved 293 individuals with confirmed cases of Covid-19 infection. This study is the first of its kind in this region to explore this connection. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Find out: this is how you clean your yoga mat! Kingdom Of Men Undo Researchers examined 293 adults diagnosed with either malaria or dengue in Mangaluru (both in the hospitals and community), a region where these vector-borne diseases are common and often associated with complications. A key finding was that individuals who had a history of Covid infection had higher chances of developing a severe form of malaria or dengue. Specifically, 85.7% of patients with severe malaria and 98.1% of those with severe dengue were previously infected with Covid-19. The participants who were positive for either malaria or dengue from Nov 2022 to Aug 2024 were selected. The study also identified other sociodemographic factors that increased the risk of severe disease. Dr Mithra added that this research points towards the possibility of persistent inflammatory responses and immunological changes caused by a previous Covid-19 infection, which might alter how the body responds to other infectious diseases like malaria and dengue, potentially leading to severe complications. This finding could help shape public health policies in regions where vector-borne diseases are endemic. Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and s ilver prices in your area.
Economic Times
an hour ago
- Economic Times
Weight-loss drug Mounjaro crosses Rs 100 crore sales in 4 months
Synopsis The drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker PharmaTrac. If this month-on-month doubling of sales continues, Mounjaro's revenue could cross Rs 500 crore by March, experts estimate. Reuters A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and a box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and made by Lilly. US drugmaker Eli Lilly's weight-loss drug Mounjaro (tirzepatide) has crossed Rs 100 crore in sales in India in just four months of launch, making it one of the country's fastest-growing prescription brands ever by value. The drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker PharmaTrac. If this month-on-month doubling of sales continues, Mounjaro's revenue could cross Rs 500 crore by March, experts estimate. After that, there could be a price erosion in the segment, as generic versions of rival GLP1 molecule semaglutide, branded as Wegovy by Danish drugmaker Novo Nordisk, are expected to flood the market. Drugs that have seen similar burgeoning growth in the past include some in the anti-diabetic category, such as Januvia (sitagliptin), Trajenta (linagliptin), Jardiance (empagliflozin), Forxiga (dapagliflozin), and Rybelsus (oral semaglutide). Wegovy, launched in early June, also saw a doubling of sales numbers with cumulative sales of the first two months at Rs 10 crore. 'Though Wegovy has a strong prescriber base because of Rybelsus (oral semaglutide), substantial promotion may be needed to reach the Mounjaro patient base for the injectable market,' said Sheetal Sapale, vice president, commercial, at PharmaTrac. Mounjaro, which was launched in late March, has so far garnered a significant patient base, selling about 160,000 units versus Wegovy's 5,000. 'As competition gets tough and branded generics come into the market, volume sales will be a major decider of who goes ahead in the race as this extent of value creation will be challenging,' Sapale said. Industry experts and doctors said the higher weight loss efficacy of 20-22% from Mounjaro compared to Wegovy's 16-18% and a lower price point make it more attractive to many patients. Wegovy is currently priced between Rs 17,345 to Rs 26,050 per pen-filled injection, which is a month's dose of four once-a-week shots. Mounjaro, which is also given on a weekly basis, is priced at Rs 14,000 to Rs 17,500 for a month's Shivane, diabetology and endocrinology consultant at Jaslok Hospital & Research Centre in Mumbai, said Mounjaro has captured a major share of the market so far due to their early launch and higher weight loss efficacy. 'Diabetes patients prefer Wegovy, while non-diabetes obese patients prefer Mounjaro,' he said. Apart from chronic weight management in obesity, Mounjaro is also indicated to improve glycaemic control in adults with type-2 diabetes mellitus, which is an additional benefit. Wegovy is used for obesity treatment and selectively in reduction in risk of major adverse cardiovascular events (MACE).
Mint
2 hours ago
- Mint
Medicaid Cuts Set to Drain Revenue at Elite Teaching Hospitals
(Bloomberg) -- Few in the US healthcare sector are immune to the effects of Washington's recent cuts to Medicaid, even the cash-rich teaching hospitals affiliated with top-notch medical schools. These facilities, often known as academic medical centers or AMCs, are usually seen as the cream of the industry crop for their top-tier credit ratings and ability to churn out revenue. But federal cuts to the public health insurance program for low-income and disabled people will lead to less funding for teaching hospitals around the country. In response, they've already started to reduce staff and scale back operations. In June, Vanderbilt University Medical Center said it would lay off as much as 650 people. About 300 positions are being eliminated at the health system tied to the University of Pennsylvania, an Ivy League school. And just last week, the University of Vermont Health Network announced staff and spending cuts. Add in other industry challenges such as rising costs and labor shortages — which stretch back to the Covid-19 pandemic — and AMCs, once seen as a trophy, now look like a liability. 'It could be material potentially for individual credits,' said Brad Spielman, a vice president at Moody's Ratings, referring to Medicaid funding, which was cut by nearly $1 trillion over ten years. 'Money withdrawn is money withdrawn.' The risk to AMCs is a drop in revenue as some patients lose Medicaid coverage and reimbursements for their care decline. That could spell trouble for schools with teaching hospitals. Medical facilities contributed to 45% of their total revenue in fiscal 2023, according to a Moody's report. For universities, that income from their medical centers can be 'very good in the good times and not so great in the bad times,' said Patrick Ronk, an analyst covering higher education at Moody's. In recent years, some AMCs have increased their exposure to Medicaid patients by acquiring community hospitals in deals meant to expand their networks and boost income. Members of the Association of American Medical Colleges — which includes AMCs, medical schools and academic societies — make up just 5% of the nation's hospitals but provide about 27% of Medicaid hospitalizations. AMCs won't just be affected by Medicaid cuts, which will be phased in over the next few years. The Trump Administration has also frozen billions in research grants and moved to scale back other federal support, which will also put a strain on operations, according to Leonard Marquez, who oversees government relations and advocacy at the Association of American Medical Colleges. It adds up to 'death by a thousand cuts,' Marquez said. 'I've never seen a situation where we have so many different lines of attack coming at us.' More stories like this are available on
